LifeScan Finds Partner to Move Into CGM Market
A well-known brand of blood glucose meters, lancets, and test strips has tapped Sanvita Medical to develop sensors that integrate with its OneTouch Reveal diabetes management app.
LifeScan, best-known for its blood glucose monitoring meters and test strips, this week announced an agreement with Sanvita Medical to move into continuous glucose monitoring (CGM), which is poised to become the standard of care for the vast majority of people with diabetes who don’t use insulin.
Sanvita Medical, a subsidiary of Nova Biomedical Corp, will design a CGM sensor that will integrate with LifeScan’s OneTouch Reveal digital portfolio, including the OneTouch Reveal
LifeScan’s OneTouch brand of blood glucose meters, testing strips, lancets, and point-of-care systems are well known to individual consumers and hospitals. Spokesperson Bridget Doherty told The American Journal of Managed Care® in an email that the partnership will allow LifeScan to offer CGM as a “complement” to its current products.
“Through this agreement, LifeScan will soon be able to offer the spectrum of diabetes monitoring solutions to meet almost any need for a wide variety of patients (type 1 and type 2)—from our blood glucose monitoring products to our digital products to CGM products with Sanvita,” she said.
But others see the move as another sign of a shifting diabetes technology landscape. A year ago, Diabetes Investor analyst David Kliff
CGM has become the standard of care for those with type 1 diabetes and those with type 2 diabetes (T2D) who use multiple daily injections. Right now, most payers will not cover CGM for the larger population of people with T2D who manage their disease without insulin, even though experts believe more widespread use would lead to increased
Current CGM leaders, such as Abbott and Dexcom, are making advances and forming partnerships, such as Dexcom’s relationship with Google, that will make CGM
The announcement comes after a period of change for LifeScan. In October 2017, the company announced it would cease US sales of its insulin pumps, and the division
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025